Key facts
- Curi Bio’s last known valuation is $62.0M (Dec 2025).
- It has raised $20.1M; the latest was Later Stage VC ($10.0M) in Dec 2025.
- Notable investors include National Institutes of Health, UTC Investment, Double Capital, DS Asset Management, Dream CIS — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Curi Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Curi Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curi Bio
Developer of a human stem cell-based platform designed to facilitate the discovery of medicines by integrating human cells, systems, and data. The company's technology provides a suite of products for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research, which promotes in vivo maturation and alignment of cell types, enabling drug developers to accurately test the safety and efficacy of new drugs.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2015
- Employees
- 47
- Website
- curibio.com/
- Ownership
- Privately Held (backing)
Curi Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curi Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curi Bio in its N-PORT filings yet. We sweep new filings monthly.